Summary & Overview
HCPCS Level II J9285: Injection, olaratumab, 10 mg
HCPCS Level II code J9285 designates a 10 mg unit of olaratumab for injection, a biologic oncology therapy. Nationally, codes like J9285 matter because they standardize billing for high-cost injectable cancer treatments, facilitate payer coverage determinations, and affect site-of-service payment and utilization monitoring.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage and reimbursement considerations across major national payers, common billing and service-line contexts for hospital outpatient and physician office infusion, and the clinical context for olaratumab as an oncology monoclonal antibody.
The publication provides benchmarks where available, summarizes relevant policy updates affecting injectable biologics billing and coverage, and outlines typical service-line and site-of-service settings for J9285. It also identifies common billing modifiers and service documentation elements used with HCPCS Level II injectable drug codes. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J9285 describes the administration of injection, olaratumab, 10 mg. This code represents a billed unit of the monoclonal antibody olaratumab administered as an injectable oncology medication.
Service type: Injection (intravenous or subcutaneous) administration of a biologic oncology therapy
Typical site of service: Hospital outpatient infusion center or physician office infusion suite
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced soft tissue sarcoma receiving systemic therapy. Olaratumab is administered as an intravenous infusion, dosed per body surface area or weight, and billed as J9285 per 10 mg. The clinical workflow includes: initial oncology consultation with staging and treatment planning; pre-infusion nursing assessment (vitals, allergy review, lab checks including CBC and CMP); placement of peripheral IV or use of an implanted port; preparation of the olaratumab infusion by pharmacy under sterile conditions; administration in an outpatient infusion center, oncology clinic, or hospital outpatient department with appropriate infusion time and observation for infusion-related reactions; post-infusion monitoring and documentation of dose, lot numbers, and patient's response; and scheduling of follow-up visits and subsequent cycles. Typical sites of service are outpatient infusion centers, oncology clinics, and hospital outpatient departments. Common concurrent services include chemotherapy infusions, antiemetics, and supportive care medications. Patient scenario example: a 58-year-old male with metastatic leiomyosarcoma receiving olaratumab in combination with doxorubicin, presenting to the oncology infusion suite for cycle 2; nursing documents pre-medication, laboratory stability, and administers J9285 per the ordered dose with observation for hypersensitivity and cardiac symptoms.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|